NX-1607

• CAT Number: I043455
• CAS Number: 2573775-59-2
• Molecular Formula: C30H34F3N5O
• Molecular Weight: 537.62
• Purity: ≥95%
• Synonyms: 2-[3-[3-methyl-1-(4-methyl-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-6-[[(3S)-3-methylpiperidin-1-yl]methyl]-4-(trifluoromethyl)-3H-isoindol-1-one
• InChI: InChI=1S/C30H34F3N5O/c1-19-6-5-9-37(15-19)16-21-10-24-25(26(11-21)30(31,32)33)17-38(27(24)39)23-8-4-7-22(12-23)29(13-20(2)14-29)28-35-34-18-36(28)3/h4,7-8,10-12,18-20H,5-6,9,13-17H2,1-3H3/t19-,20?,29?/m0/s1
• InChIKey: HUOLMBXGHHSYHC-QORSJFMISA-N
• SMILES: C[C@H]1CCCN(C1)CC2=CC3=C(CN(C3=O)C4=CC=CC(=C4)C5(CC(C5)C)C6=NN=CN6C)C(=C2)C(F)(F)F

NX-1607（Cat No.:I043455）is an experimental small-molecule drug being investigated for its potential in cancer immunotherapy. It acts as an immune modulator, designed to enhance the body’s immune response against tumors. NX-1607 works by targeting specific signaling pathways involved in immune evasion by tumors, potentially reactivating immune cells such as T-cells to better recognize and attack cancer cells. The drug is being studied in clinical trials for its ability to treat various solid tumors, including those that are resistant to current therapies, by improving immune system efficacy in the tumor microenvironment.